Formycon AG
XETRA:FYB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Formycon AG
Cash Equivalents
Formycon AG
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formycon AG
XETRA:FYB
|
Cash Equivalents
€68.8m
|
CAGR 3-Years
91%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash Equivalents
€481.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash Equivalents
€345.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Cash Equivalents
$15.5m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-15%
|
|
|
Biotest AG
XETRA:BIO
|
Cash Equivalents
€41.8m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
Formycon AG
Glance View
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
See Also
What is Formycon AG's Cash Equivalents?
Cash Equivalents
68.8m
EUR
Based on the financial report for Dec 31, 2025, Formycon AG's Cash Equivalents amounts to 68.8m EUR.
What is Formycon AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
10%
Over the last year, the Cash Equivalents growth was 65%. The average annual Cash Equivalents growth rates for Formycon AG have been 91% over the past three years , 10% over the past five years .
